Prosight Management, LP Aldeyra Therapeutics, Inc. Transaction History

Prosight Management, LP

$372 Million
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $1.66 Million - $2.78 Million	-233,936 Reduced 61.01%	149,511 $1.25 Million
Q1 2023 May 12, 2023	SELL	$5.77 - $9.93 $2.74 Million - $4.72 Million	-475,262 Reduced 55.35%	383,447 $3.81 Million
Q4 2022 Feb 14, 2023	SELL	$5.08 - $7.09 $1.79 Million - $2.5 Million	-352,091 Reduced 29.08%	858,709 $5.98 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $2.95 Million - $6 Million	-775,083 Reduced 39.03%	1,210,800 $6.47 Million
Q2 2022 Aug 12, 2022	BUY	$2.43 - $4.85 $1.42 Million - $2.84 Million	585,644 Added 41.82%	1,985,883 $7.92 Million
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $796,051 - $1.27 Million	244,939 Added 21.2%	1,400,239 $6.22 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $1.47 Million - $4.05 Million	420,300 Added 57.18%	1,155,300 $4.62 Million
Q3 2021 Nov 12, 2021	BUY	$7.94 - $11.31 $1.11 Million - $1.58 Million	139,761 Added 23.48%	735,000 $6.45 Million
Q2 2021 Aug 13, 2021	BUY	$10.44 - $14.85 $1.27 Million - $1.81 Million	121,793 Added 25.72%	595,239 $6.74 Million
Q1 2021 May 14, 2021	SELL	$6.53 - $14.42 $2.84 Million - $6.27 Million	-435,042 Reduced 47.89%	473,446 $5.63 Million
Q4 2020 Feb 12, 2021	SELL	$6.31 - $8.13 $1.16 Million - $1.49 Million	-183,512 Reduced 16.81%	908,488 $6.23 Million
Q3 2020 Nov 13, 2020	SELL	$4.0 - $7.53 $2.11 Million - $3.98 Million	-528,200 Reduced 32.6%	1,092,000 $8.09 Million
Q2 2020 Aug 14, 2020	SELL	$1.97 - $5.05 $817,825 - $2.1 Million	-415,140 Reduced 20.4%	1,620,200 $6.76 Million
Q1 2020 May 15, 2020	BUY	$1.62 - $6.4 $983,442 - $3.89 Million	607,063 Added 42.5%	2,035,340 $5.03 Million
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $3.02 Million - $5.09 Million	638,049 Added 80.74%	1,428,277 $8.3 Million
Q3 2019 Nov 14, 2019	BUY	$4.41 - $6.12 $407,073 - $564,918	92,307 Added 13.23%	790,228 $4.17 Million
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $687,726 - $1.03 Million	114,621 Added 19.65%	697,921 $4.19 Million
Q1 2019 May 15, 2019	BUY	$7.14 - $9.85 $1.28 Million - $1.76 Million	178,837 Added 44.22%	583,300 $5.27 Million
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $2.94 Million - $5.38 Million	404,463 New	404,463 $3.36 Million

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.4M

Call Options Held

196K

Put Options Held

142K

Perceptive Advisors LLC New York, NY

9.28M
Shares

$45 Million
1.31% of portfolio
Knoll Capital Management, LLC Miami, FL

5.48M
Shares

$26.6 Million
14.56% of portfolio
Vanguard Group Inc Valley Forge, PA

3.76M
Shares

$18.2 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.62M
Shares

$17.6 Million
0.0% of portfolio
Kennedy Capital Management, Inc. St Louis, MO

1.88M
Shares

$9.12 Million
0.24% of portfolio

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.

Account